The post Story Protocol rallies on Asian demand – But THESE IP signals urge caution appeared on BitcoinEthereumNews.com. While most intellectual property–focusedThe post Story Protocol rallies on Asian demand – But THESE IP signals urge caution appeared on BitcoinEthereumNews.com. While most intellectual property–focused

Story Protocol rallies on Asian demand – But THESE IP signals urge caution

While most intellectual property–focused tokens lagged during the market rebound, Story Protocol [IP] broke higher.

The token gained roughly 25% within 24 hours, marking its strongest daily performance in recent weeks. Buyers stepped in as broader conditions stabilized.

Asian investors light the fuse

Trading activity surged alongside price, with total IP volume jumping by roughly 789% during the rally. Daily trading volume climbed to $157 million as investors aggressively exchanged positions.

Data pointed to Asian traders as the main force behind the move. South Korea–based Upbit accounted for 45% of total trading volume, translating to $70.8 million—nearly half of all activity. In contrast, U.S.-based Coinbase recorded just 2.82% of volume.

The exact trigger behind the sudden rush of interest from Asian investors remains unclear. However, the impact is visible in the speed and strength of IP’s advance.

Source: CoinMarketCap

Perpetual market positioning also leaned cautiously bullish.

Long positions slightly outweighed shorts over the past day, reflecting modest upside positioning. At press time, the Long/Short Ratio hovered near 1.00, indicating balance rather than conviction.

Momentum builds, but caution lingers

Despite the improving structure, technical indicators suggest that optimism may not run unchallenged.

On the chart, IP formed a cup-and-handle pattern, a structure often associated with continuation. Confirmation, however, remained incomplete.

The Accumulation/Distribution (A/D) indicator stayed in negative territory, signaling lingering sell-side pressure. Although the reading improved from roughly -63.8 million to near -63.3 million, net distribution persisted.

Source: TradingView

Meanwhile, the Money Flow Index (MFI) painted a more stretched picture.

IP’s Money Flow Index climbed above 90, well into overbought territory. Such readings historically increase pullback risk. That imbalance suggested recent gains may face consolidation before further upside.

Perpetual sellers tighten their grip

While the perpetual market volume has tilted slightly in favor of bulls, the broader perpetual market paints a more restrained picture.

The Open Interest–Weighted Funding Rate, which tracks whether traders are opening more long or short contracts, shows stronger sell-side participation.

Source: CoinGlass

A positive Funding Rate points to seller dominance, while a negative reading signals buyer control. Data at press time showed a negative reading of -0.1638, confirming that sellers continue to hold the upper hand in the perpetual market.

This growing sell-side pressure loads the downside risk and suggests that IP’s rally, while impressive, may face resistance before any sustained continuation.


Final Thoughts

  • Story Protocol’s [IP] rally reflected strong spot demand, but Derivatives positioning showed traders remained cautious.
  • That divergence may keep volatility elevated as price searches for confirmation. Whether buyers regain control could shape IP’s next decisive move.

Next: ‘End of an era’ as Ethereum OG exits after $274mln sale – Details

Source: https://ambcrypto.com/story-protocol-rallies-on-asian-demand-but-these-ip-signals-urge-caution/

Market Opportunity
Story Logo
Story Price(IP)
$2.295
$2.295$2.295
-5.63%
USD
Story (IP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26